Senti Biosciences, Inc. (NASDAQ:SNTI) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Senti Biosciences, Inc. (NASDAQ:SNTI) have been assigned a consensus rating of “Moderate Buy” from the five brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $8.75.

SNTI has been the topic of several research reports. Wall Street Zen upgraded Senti Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 28th. Chardan Capital raised their price target on Senti Biosciences from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a research note on Tuesday, April 21st.

Hedge Funds Weigh In On Senti Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its stake in Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after purchasing an additional 117,588 shares during the last quarter. Citadel Advisors LLC purchased a new position in Senti Biosciences in the third quarter valued at about $117,000. Armistice Capital LLC purchased a new position in Senti Biosciences in the second quarter valued at about $1,883,000. Virtu Financial LLC purchased a new position in Senti Biosciences in the fourth quarter valued at about $46,000. Finally, Jane Street Group LLC purchased a new position in Senti Biosciences in the fourth quarter valued at about $40,000. Hedge funds and other institutional investors own 25.70% of the company’s stock.

Senti Biosciences Trading Up 0.4%

Shares of Senti Biosciences stock opened at $0.98 on Friday. The firm has a market cap of $30.65 million, a P/E ratio of -0.51 and a beta of 2.09. Senti Biosciences has a 12 month low of $0.77 and a 12 month high of $3.88. The stock’s fifty day moving average price is $0.95 and its 200-day moving average price is $1.18.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.22. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. Analysts forecast that Senti Biosciences will post -1.16 earnings per share for the current year.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.